UBA1 and Thromboembolism: In addition, the clonal amplification of UBA1 was observed in patients, suggesting that the efficacy of ruxolitinib is related to its anti-inflammatory properties rather than to the eradication of UBA1 mutations.30, 63However, side effects associated with JAK inhibitors are common, including severe opportunistic bacterial and viral infections including mycobacterium tuberculosis and herpes zoster virus, anemia, leukopenia, and thromboembolism.